Sichuan Kelun Pharmaceutical (002422.SZ): Diqu Yuanketon tablets receive drug registration approval.

Sichuan Kelun Pharmaceutical (002422.SZ) announced that their chemical drug, Diquythrona tablets, has recently obtained approval from the National Medical Products Administration. This Diquythrona tablet is one of the first three domestic products to receive approval, which will further enhance the company's competitiveness in the field of reproductive health. It is reported that Diquythrona tablets were developed by Abbott and are currently marketed in over 100 countries. They are used to treat related diseases caused by endogenous progesterone deficiency, such as dysmenorrhea, endometriosis, threatened miscarriage or habitual miscarriage caused by progesterone deficiency, and luteal support in assisted reproductive technology.